2026-10-13T10:50:43Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88062024-03-13T01:05:23Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Santos García, Diego Deus-Fonticoba, Teresa de Cores Bartolomé, Carlos Muñoz, Guillermo Paz González, José Manuel Martínez Miró, Cristina Suárez Castro, Ester Jesús, Silvia Aguilar, Miquel Pastor, Pau Planellás, Lluis L. Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Hernández Vara, Jorge Cabo López, Iria López Manzanares, Luis González Aramburu, Isabel López Manzanares, Luis González Aramburu, Isabel Ávila Rivera, María A. Catalán, María José Nogueira, Víctor Puente, Víctor Ruíz de Arcos, María Borrue, Carmen Solano Vila, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Clavero Ibarra, Pedro Kulisevsky Bojarsky, Jaume Blázquez Estrada, Marta Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. Fabregues, Oriol de González Ardura, Jessica Ordás Bandera, Carlos Manuel López Díaz, Luis M. McAfee, Darrian Martínez Martín, Pablo Mir, Pablo COPPADIS Study Group 2024-03-12T11:11:14Z 2024-03-12T11:11:14Z 2021-12 http://hdl.handle.net/10259/8806 10.1038/s41531-021-00256-w 2373-8057 Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R 2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients. application/pdf eng Springer Nature npj Parkinson's Disease. 2021, V. 7, n. 1 https://doi.org/10.1038/s41531-021-00256-w Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Predictors of clinically significant quality of life impairment in Parkinson’s disease info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion npj Parkinson's Disease 7 1